Current Report Filing (8-k)
November 15 2021 - 07:47AM
Edgar (US Regulatory)
false 0001830214 0001830214 2021-11-15
2021-11-15 0001830214 us-gaap:CommonClassAMember 2021-11-15
2021-11-15 0001830214 us-gaap:WarrantMember 2021-11-15
2021-11-15
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 15,
2021
GINKGO BIOWORKS HOLDINGS, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
Delaware |
|
001-40097 |
|
87-2652913 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
27 Drydock Avenue
8th Floor
Boston, MA 02210
(Address of Principal Executive Offices, including zip code)
Registrant’s telephone number, including area code: (877)
422-5362
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
| |
☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
| |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
| |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
| |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
Class A common stock, par value
$0.0001 per share |
|
DNA |
|
NYSE |
|
Warrants to purchase one share of
Class A common stock, each at an exercise price of $11.50 per
share |
|
DNA.WS |
|
NYSE |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02 Results of Operations and Financial Condition.
On November 15, 2021, Ginkgo Bioworks Holdings, Inc. issued a
press release reporting its financial results for the third quarter
ended September 30, 2021. A copy of the press release is
furnished as Exhibit 99.1 to this Current Report on Form
8-K.
The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1
attached hereto) shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly provided by specific reference in
such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
GINKGO BIOWORKS HOLDINGS, INC. |
|
|
|
|
| Date: November 15, 2021 |
|
|
|
By: |
|
/s/ Mark Dmytruk
|
|
|
|
|
Name: |
|
Mark
Dmytruk |
|
|
|
|
Title: |
|
Chief
Financial Officer |
Ginkgo Bioworks (NYSE:DNA)
Historical Stock Chart
From Apr 2022 to May 2022
Ginkgo Bioworks (NYSE:DNA)
Historical Stock Chart
From May 2021 to May 2022
